Ticker: ABUS

Arbutus Biopharma Corporation (NASDAQ: ABUS) has reported significant changes in its financial condition for the second quarter and first half of the year 2025. The company operates in the biopharmaceutical sector, focusing on the development of treatments for chronic hepatitis B (cHBV). Positive...

Company Overview Arbutus Biopharma Corporation (NASDAQ: ABUS) is a clinical-stage biopharmaceutical company focused on developing therapies for chronic hepatitis B (cHBV). They have two lead candidates: imdusiran (AB-729), an RNAi therapeutic, and AB-101, a PD-L1 inhibitor. The company is activel...